Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

Fig. 3

Changes in exacerbations and ER visits for the patients who experienced these events at baseline. a Exacerbation reduction: There was a 69.0 % ~87.5 % reduction in exacerbations after omalizumab discontinuation compared with baseline. b ER reduction: There was a 29.4 % ~ 36.5 % reduction of ER visit after omalizumab discontinuation compared with baseline

Back to article page